1. Belzutifanas

This tender, originating from Lithuania and sourced via ted, is for '1. Belzutifanas'. The content specifies 'Nauji vaistiniai preparatai, kompensuojami iš Retų ligų fondo', which translates to 'New medicinal products, compensated from the Rare Diseases Fund'. This tender is for the procurement of a specific pharmaceutical product, Belzutifanes, intended for patients with rare diseases, with funding provided by a specialized fund. Typical requirements for pharmaceutical tenders include detailed specifications of the drug, such as its active ingredient, dosage form, strength, packaging, and compliance with pharmacopoeia standards and relevant pharmaceutical regulations (e.g., EMA approval). Bidders must provide evidence of marketing authorization, product registration in Lithuania, and the ability to guarantee a stable supply chain. Quality assurance documentation, including Good Manufacturing Practice (GMP) certification, is usually mandatory. The tender likely specifies delivery requirements, storage conditions, and expiry date management. Evaluation criteria will focus on the drug's compliance with specifications, price, availability, and the supplier's reliability. The objective is to ensure access to essential medication for patients suffering from rare diseases.